Revenue Projections and Financial Milestones

Following FDA and out-of-U.S. (OUS) regulatory approval, we anticipate significant financial growth and achievement of key milestones.

Revenue Projections

  • Projected Global Revenue: We forecast a reasonable global revenue of $80 million by Year 7 following commercialization.
  • Cash Flow Positivity: Expected to become cash flow positive by Year 2.
  • Gross Margin: Anticipated gross margin is approximately 80% across all products.
  • Exit Strategy: A likely exit opportunity is projected between Years 3 and 4.

OculoPULSE: A New Paradigm in Ocular Vascular Disease Management

Key Advantages

  • Early-Stage Intervention: Leveraging novel disease biomarkers for timely intervention.
Experienced Team
Our management team brings a wealth of expertise and a proven track record.
Technical Feasibility
Demonstrated capability to realize the technological aspects of our products.
Established Mechanism of Action
Clear understanding of how our technology operates within the ocular system.
Strong Intellectual Property Position
Solid IP portfolio that safeguards our innovations.
Physician Engagement
Active involvement and encouragement from healthcare professionals.
Three blue-tinted lenses showcasing optical product design

Funding Goal

We are seeking $2.5 million to secure FDA clearance and drive early commercialization efforts.
Theresa Kramer, MD
Founder, President, CEO & CMOTel: (520) 904-7984Email
Address
12020 Deer Bit Lane, Suite AGlen Arm, MD 21057 Service Area: Nationwide with Future Global
Hours of Operation
Monday-Friday, 9 a.m.-5 p.m.
© 2026 OculoPULSE. All rights reserved